Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may offer a significant step forward for body management . Initial clinical trials have indicated considerable decreases in body mass , possibly surpassing current obesity medications . Despite this, further evalua